Klug S, Felies A, Stürje H, Nogueira A C, Neubert R, Frankus E
Universitätsklinikum Rudolf Virchow, Freie Universität Berlin, Institut für Toxikologie und Embryopharmakologie, Germany.
Arch Toxicol. 1994;68(3):203-5. doi: 10.1007/s002040050055.
The teratogenic potency of the thalidomide (Thd) derivative phthalimidophthalimide (Phtpht) was assessed in the common marmoset (Callithrix jacchus), by oral administration of the relatively high daily dose of 50 mg Phtpht/kg body wt, during the susceptible period (days 48-61 of pregnancy). Since in this species daily doses of only 100 micrograms/kg body wt of the Thd derivative EM12 already induce typical gross structural abnormalities in nearly 100% of the fetuses, investigations with a small number of these New World monkeys allow a rough estimation of the teratogenic potency of Thd-type substances. Macroscopic inspection and skeletal evaluation of ten fetuses gave no indication of dysmorphogenesis following treatment with Phtpht. We conclude that Phtpht has little, if any, Thd-type teratogenic potency in this non-human primate.
通过在妊娠易感期（妊娠第48 - 61天）给普通狨猴（绢毛猴）口服相对高剂量的50毫克邻苯二甲酰亚氨基邻苯二甲酸酯（Phtpht）/千克体重，评估了沙利度胺（Thd）衍生物邻苯二甲酰亚氨基邻苯二甲酸酯的致畸效力。由于在该物种中，仅100微克/千克体重的Thd衍生物EM12的每日剂量就已在近100%的胎儿中诱发典型的大体结构异常，因此对少量这些新大陆猴进行的研究可以粗略估计Thd类物质的致畸效力。对10只胎儿进行的宏观检查和骨骼评估未显示Phtpht处理后有畸形发生。我们得出结论，在这种非人灵长类动物中，Phtpht几乎没有（如果有的话）Thd类致畸效力。
